Full Text Journal Articles by
Author Guillermo Quintero

Advertisement

Find full text journal articles








Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study.

Federico Longo, Mónica Jorge, Ricardo Yaya, Ana Fernández Montes, Nieves Martínez Lago, Elena Brozos, Jorge Aparicio, Guillermo Quintero, Eduardo Ceballos, Elvira Buxó, Ana Maria Lopez, Maria Luz Pellón, Raquel Molina, Laura Diaz-Paniagua, Paula Cerdà, Pedro Lopez Leiva, Alfonso Martín Carnicero, Antía Cousillas, Lorena Paris, Beatriz García-Paredes, Carlos Romero, María Ortega, Alberto Molero, Sergio de la Torre, Min-Hua Jen, Silvia Díaz-Cerezo,

<b>Aims:</b> To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). <b>Methods:</b> Observational, retrospective study carried out in 20 Spanish hospitals, in patients who started ramucirumab treatment between December 2015 and December 2018. Descriptive analysis was conducted for ... Read more >>

Future Oncol (Future oncology (London, England))
[2021, 17(14):1777-1791]

Cited: 0 times

View full text PDF listing >>



Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study.

Camila Peña, Eloisa Riva, Natalia Schutz, Luz Tarín-Arzaga, Humberto Martínez-Cordero, Virginia Bove, Rocío Osorio, Mauricio Chandía, Cecilia Beltrán, Javier Schulz, Daniela Cardemil, Carolina Contreras, Carmen Gloria Vergara, Javiera Donoso, Marcela Espinoza, Gabriel La Rocca, Hernán López-Vidal, Pilar León, Christine Rojas Hopkins, Pablo Soto, Sandra Aranda, Vivianne Torres, Macarena Roa, Paola Ochoa, Patricio Jose Duarte, Guillermina Remaggi, Sebastián Yantorno, Ariel Corzo, Soledad Zabaljauregui, Claudia Shanley, Sergio Lopresti, Sergio Orlando, Verónica Verri, Luis Quiroga, Carlos García, Vanesa Fernández, Jhoanna Ramirez, Alicia Molina, María Pacheco, Alex Mite, Inés Reyes, Brenner Sabando, Francisca Ramírez, Claudia Sossa, Virginia Abello, Henry Idrobo, Kenny Mauricio Galvez Cardenas, Domingo Saavedra, Guillermo Quintero, Raimundo Gazitúa, Lina Gaviria, Rigoberto Gomez, Mónica Osuna, Alicia Henao-Uribe, Omar Cantú-Martínez, David Gómez-Almaguer, Yarely Itzayana García-Navarrete, Antonio Cruz-Mora, Yahveth Cantero-Fortiz, Guillermo J Ruiz-Argüelles, Dorotea Fantl,

The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival ... Read more >>

Leuk Lymphoma (Leukemia & lymphoma)
[2020, 61(13):3112-3119]

Cited: 0 times

View full text PDF listing >>



Advertisement

Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.

Javier Sastre, Virginia de la Orden, Antonio Martínez, Inmaculada Bando, Milagros Balbín, Beatriz Bellosillo, Sarai Palanca, Maria Isabel Peligros Gomez, Beatriz Mediero, Patricia Llovet, Virginia Moreno Moral, José Maria Viéitez, Pilar García-Alfonso, Silvia Gil Calle, Maria José Ortiz-Morales, Antonieta Salud, Guillermo Quintero, Carlos Lopez, Eduardo Díaz-Rubio, Enrique Aranda, ,

<h4>Background</h4>Clinicopathologic characteristics and prognostic and predictive factors offer valuable guidance when selecting optimal first-line treatment in patients with metastatic colorectal cancer (CRC). The association between baseline circulating tumor cell (bCTC) count, molecular tumor profile, and clinicopathologic features was analyzed in a chemo-naïve metastatic CRC population.<h4>Patients and methods</h4>A total of 1202 ... Read more >>

Clin Colorectal Cancer (Clinical colorectal cancer)
[2020, 19(3):e110-e116]

Cited: 2 times

View full text PDF listing >>



Pilot Study of an Integrative New Tool for Studying Clinical Outcome Discrimination in Acute Leukemia.

María José Gacha-Garay, Andrés Felipe Niño-Joya, Natalia I Bolaños, Lina Abenoza, Guillermo Quintero, Humberto Ibarra, John M Gonzalez, Verónica Akle, Zayra V Garavito-Aguilar,

Acute leukemia is a heterogeneous set of diseases affecting children and adults. Current prognostic factors are not accurate predictors of the clinical outcome of adult patients and the stratification of risk groups remains insufficient. For that reason, this study proposes a multifactorial analysis which integrates clinical parameters, <i>ex vivo</i> tumor ... Read more >>

Front Oncol (Frontiers in oncology)
[2019, 9:245]

Cited: 4 times

View full text PDF listing >>



Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.

Ana Fernández, Mercedes Salgado, Adelaida García, Elvira Buxò, Ruth Vera, Jorge Adeva, Paula Jiménez-Fonseca, Guillermo Quintero, Cristina Llorca, Mamen Cañabate, Luis Jesús López, Andrés Muñoz, Patricia Ramírez, Paula González, Carlos López, Margarita Reboredo, Elena Gallardo, Manuel Sanchez-Cánovas, Javier Gallego, Carmen Guillén, Nuria Ruiz-Miravet, Víctor Navarro-Pérez, Juan De la Cámara, Inmaculada Alés-Díaz, Roberto Antonio Pazo-Cid, Alberto Carmona-Bayonas,

<h4>Background</h4>Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide useful information to support decision-making processes in routine practice.<h4>Methods</h4>Retrospective, multicenter study including patients with metastatic pancreatic cancer, who started first-line ... Read more >>

BMC Cancer (BMC cancer)
[2018, 18(1):1185]

Cited: 4 times

View full text PDF listing >>



Primary CNS plasmablastic lymphoma in an HIV/EBV negative patient: A case report.

Martha Romero, Guido R González-Fontal, Carlos Saavedra, Joaquín Guerra, Guillermo Quintero, Sandra Quijano, Douglas Ney, Andrés F Henao-Martínez,

Diagn Cytopathol (Diagnostic cytopathology)
[2016, 44(1):61-65]

Cited: 4 times

View full text PDF listing >>



Polyangiitis with granulomatosis as a paraneoplastic syndrome of B-cell lymphoma of the lacrimal gland.

Beatriz Wills Sanín, Yenny R Cárdenas Bolivar, Jose J Carvajal, Guillermo E Quintero, Rafael Andrade,

Introduction. The clinical course of an autoimmune paraneoplastic syndrome parallels the natural history of the primary malignancy. In most cases, such paraneoplastic are syndromes hardly distinguishable from idiopathic autoimmune diseases. A case of polyangiitis with granulomatosis as a paraneoplastic syndrome in a patient with B-cell Lymphoma of the lacrimal gland ... Read more >>

Case Rep Hematol (Case reports in hematology)
[2014, 2014:713048]

Cited: 1 time

View full text PDF listing >>



Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).

Julen Fernandez-Plana, Carlos Pericay, Guillermo Quintero, Vicente Alonso, Antonieta Salud, Miguel Mendez, Mercedes Salgado, Eugeni Saigi, Luis Cirera, ,

<h4>Background</h4>This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS colorectal cancer.<h4>Methods</h4>Previously untreated patients with wild-type KRAS tumours received biweekly cetuximab (500 mg/m2 on day 1) plus FOLFOX-4 (oxaliplatin 85 mg/m2 ... Read more >>

BMC Cancer (BMC cancer)
[2014, 14:865]

Cited: 7 times

View full text PDF listing >>



Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.

Carlos Grande, Guillermo Quintero, Sonia Candamio, Lorena París Bouzas, María José Villanueva, Begoña Campos, Elena Gallardo, Elena Alvarez, Joaquín Casal, José Ramón Mel, ,

<h4>Objective</h4>The combination of oxaliplatin and oral capecitabine (XELOX) has shown to be an active regimen in metastatic colorectal cancer (MCRC). However, the experience with XELOX in elderly patients is limited. This study aimed to evaluate the efficacy and safety of XELOX as first-line treatment in elderly patients with MCRC.<h4>Patients and ... Read more >>

J Geriatr Oncol (Journal of geriatric oncology)
[2013, 4(2):114-121]

Cited: 3 times

View full text PDF listing >>



The combined expression patterns of Ikaros isoforms characterize different hematological tumor subtypes.

Carlos A Orozco, Andrés Acevedo, Lazaro Cortina, Gina E Cuellar, Mónica Duarte, Liliana Martín, Néstor M Mesa, Javier Muñoz, Carlos A Portilla, Sandra M Quijano, Guillermo Quintero, Miriam Rodriguez, Carlos E Saavedra, Helena Groot, María M Torres, Valeriano López-Segura,

A variety of genetic alterations are considered hallmarks of cancer development and progression. The Ikaros gene family, encoding for key transcription factors in hematopoietic development, provides several examples as genetic defects in these genes are associated with the development of different types of leukemia. However, the complex patterns of expression ... Read more >>

PLoS One (PloS one)
[2013, 8(12):e82411]

Cited: 4 times

View full text PDF listing >>



Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.

Mercedes Salgado, Margarita Reboredo, Juan Carlos Mendez, Guillermo Quintero, María Luz Pellón, Carlos Romero, Mónica Jorge, Ana Fernández Montes, Manuel Valladares-Ayerbes, Manuel Ramos, Silvia Varela, Miguel Ángel Alonso, ,

<h4>Aim</h4>To evaluate gemcitabine plus capecitabine as third-line or later-line therapy in patients with refractory advanced colorectal cancer (CRC) who maintain a good performance status (PS).<h4>Patients and methods</h4>We retrospectively evaluated patients who had failed at least two lines of therapy or had contraindication to standard therapy and received gemcitabine (1,000 mg/m(2), ... Read more >>

Anticancer Res (Anticancer research)
[2013, 33(9):4089-4096]

Cited: 3 times

View full text PDF listing >>





Advertisement


Disclaimer

1.0624 s